Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions

Modern Pathology

Volumn 25, Issue 7, 2012, Pages 930-937

  Troxell, Megan L ^a   Brunner, Alayne L ^b   Neff, Tanaya ^a   Warrick, Andrea ^a   Beadling, Carol ^a   Montgomery, Kelli ^b   Zhu, Shirley ^b   Corless, Christopher L ^a   West, Robert B ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; columnar cell lesion; PIK3CA

Indexed keywords

DNA; FORMALDEHYDE; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; BREAST CELL; CANCER PATIENT; CANCER SCREENING; CELL DAMAGE; CLINICAL ARTICLE; COLUMNAR EPITHELIUM; CONTROLLED STUDY; DNA EXTRACTION; GENE MUTATION; GENETIC SCREENING; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MASS SPECTROMETRY; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; WILD TYPE;

BREAST DISEASES; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 84863441069     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.55     Document Type: Article

References (58)

1. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006;94:455-459. (Pubitemid 43289745)
2. Castaneda CA, Cortes-Funes H, Gomez HL, et al. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev 2010;29: 751-759.
3. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008;27:5486-5496.
4. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-619. (Pubitemid 44100518)
5. Wymann MP, Marone R. Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol 2005;17:141-149. (Pubitemid 40380937)
6. McAuliffe PF, Meric-Bernstam F, Mills GB, et al. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 2010;10(Suppl 3):S59-S65.
7. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-562.
8. Samuels Y,Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. (Pubitemid 38541907)
9. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;3:772-775. (Pubitemid 41351083)
10. Troxell ML. PIK3CA/AKT1 mutations in breast carcinoma: a comprehensive review of experimental and clinical studies. J Clin Exp Pathol 2012; doi: 10.4172/2161-0681.S1-002.
11. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-444. (Pubitemid 47123510)
12. Dunlap J, Le C, Shukla A, et al. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 2010;120:409-418.
13. Li H, Zhu R, Wang L, et al. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast. Exp Mol Pathol 2010;88:150-155.
14. Miron A, Varadi M, Carrasco D, et al. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 2010;70:5674-5678.
15. Kalinsky K, Heguy A, Bhanot UK, et al. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Res Treat 2011;129:635-643.
16. Troxell ML, Levine J, Beadling C, et al. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Mod Pathol 2010;23: 27-37.
17. Schnitt SJ, Vincent-Salomon A. Columnar cell lesions of the breast. Adv Anat Pathol 2003;10:113-124.
18. Abdel-Fatah TM, Powe DG, Hodi Z, et al. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol 2007;31: 417-426. (Pubitemid 46673116)
19. Moinfar F. Flat ductal intraepithelial neoplasia of the breast: a review of diagnostic criteria, differential diagnoses, molecular-genetic findings, and clinical relevance-it is time to appreciate the Azzopardi concept!. Arch Pathol Lab Med 2009;133:879-892.
20. Lerwill MF. Flat epithelial atypia of the breast. Arch Pathol Lab Med 2008;132:615-621. (Pubitemid 351489615)
21. Tavassoli F, Hoefler H, Rosai J, et al. Flat epithelial atypia. In: Tavassoli F, Devilee P (eds). Tumous of the Breast and Female Genital Organs Vol. IARC Press: Lyon, 2003, pp 65-66.
22. Moinfar F, Man YG, Bratthauer GL, et al. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type (00clinging ductal carcinoma in situ00): a simulator of normal mammary epithelium. Cancer 2000;88:2072-2081. (Pubitemid 30233209)
23. Reis-Filho JS, Lakhani SR. The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res 2003;5:313-319.
24. Simpson PT, Gale T, Reis-Filho JS, et al. Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol 2005;29:734-746. (Pubitemid 40734423)
25. Dabbs DJ, Carter G, Fudge M, et al. Molecular alterations in columnar cell lesions of the breast. Mod Pathol 2006;19:344-349. (Pubitemid 43276987)
26. Abdel-Fatah TM, Powe DG, Hodi Z, et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol 2008;32:513-523. (Pubitemid 351458293)
27. Ellsworth RE, Ellsworth DL, Weyandt JD, et al. Chromosomal alterations in pure nonneoplastic breast lesions: implications for breast cancer progression. Ann Surg Oncol 2010;17:1688-1694.
28. Stacher E, Boldt V, Leibl S, et al. Chromosomal aberrations as detected by array comparative genomic hybridization in early low-grade intraepithelial neoplasias of the breast. Histopathology 2011;59:549-555.
29. Beadling C, Heinrich MC, Warrick A, et al. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn 2011;13:504-513.
30. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-7681. (Pubitemid 39446895)
31. Li SY, Rong M, Grieu F, et al. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2006;96:91-95.
32. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008;68:6084-6091.
33. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to- mesenchymal transition and stem cell characteristics. Cancer Res 2009;69:4116-4124.
34. Buttitta F, Felicioni L, Barassi F, et al. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 2006;208:350-355. (Pubitemid 43210521)
35. Liang X, Lau QC, Salto-Tellez M, et al. Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese. Cancer Biol Ther 2006;5:544-548. (Pubitemid 43765291)
36. Maruyama N, Miyoshi Y, Taguchi T, et al. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 2007;13:408-414. (Pubitemid 46225343)
37. Perez-Tenorio G, Alkhori L, Olsson B, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007;13:3577-3584. (Pubitemid 46955118)
38. Benvenuti S, Frattini M, Arena S, et al. PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat 2008;29:284-288. (Pubitemid 351240601)
39. Loi S, Haibe-Kains B, Majjaj S, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptorpositive breast cancer. Proc Natl Acad Sci USA 2010;107:10208-10213.
40. Ellis MJ, Lin L, Crowder R, et al. Phosphatidylinositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 2010;119:379-390.
41. Bozhanov SS, Angelova SG, Krasteva ME, et al. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. J Cancer Res Clin Oncol 2010;136:1657-1669.
42. Boyault S, Drouet Y, Navarro C, et al. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat 2011;132:29-39.
43. Cizkova M, Cizeron-Clairac G, Vacher S, et al. Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway. PLoS One 2010;5:e15647.
44. Kalinsky K, Jacks LM, Heguy A, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009;15:5049-5059.
45. Dupont Jensen J, Laenkholm AV, Knoop A, et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 2011;17:667-677.
46. Vorkas PA, Poumpouridou N, Agelaki S, et al. PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method. J Mol Diagn 2010;12: 697-704.
47. Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011;17:1169-1180.
48. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, et al. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 2011;10:1093-1101.
49. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532.
50. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-1113. (Pubitemid 350134889)
51. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003;100:5974-5979. (Pubitemid 36576916)
52. Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 2005;143:446-457. (Pubitemid 41338942)
53. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402. (Pubitemid 47539306)
54. Park BH, Davidson NE. PI3 kinase activation and response to Trastuzumab Therapy: what0s neu with herceptin resistance? Cancer Cell 2007;12:297-299. (Pubitemid 47539315)
55. Nahta R, Yu D, Hung MC, et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3: 269-280. (Pubitemid 43731112)
56. O0Brien NA, Browne BC, Chow L, et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010;9:1489-1502.
57. Di Cosimo S, Baselga J. Phosphoinositide 3-kinase mutations in breast cancer: a 00good00 activating mutation? Clin Cancer Res 2009;15:5017-5019.
58. Liu P, Cheng H, Santiago S, et al. Oncogenic PIK3CAdriven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med 2011;17:1116-1120.